deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02389985

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

A Phase Ib/II Study of CRLX101 in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Sponsor: NewLink Genetics Corporation

Conditions Ovarian Cancer
Interventions CRLX101 Paclitaxel
Updated 12 times since 2017 Last updated: May 26, 2020 Started: Jul 31, 2015 Primary completion: Jun 4, 2018 Completion: Oct 18, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Company decision

Other terminated trials from NewLink Genetics Corporation

More terminations from NewLink Genetics Corporation

Other Ovarian Cancer trials with similar outcome

Browse all Ovarian Cancer trials

Listed as NCT02389985, this PHASE1/PHASE2 trial focuses on Ovarian Cancer and remains terminated or withdrawn. Sponsored by NewLink Genetics Corporation, it has been updated 12 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~May 2017 · 3 months · monthly snapshotActive Not Recruiting~May 2017 – ~Jun 2018 · 13 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshotActive Not Recruiting~Mar 2019 – ~Jun 2019 · 3 months · monthly snapshotTerminated~Jun 2019 – ~Jun 2020 · 12 months · monthly snapshotTerminated~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshotTerminated~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotTerminated~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Apr 2022 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  5. Jan 2021 — Apr 2022 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 7 earlier versions

  1. Jun 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

  2. Jun 2019 — Jun 2020 [monthly]

    Terminated PHASE1_PHASE2

  3. Mar 2019 — Jun 2019 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

  4. Jun 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. May 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NewLink Genetics Corporation
Data source: Lumos Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations